Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
nasdaq bounce!
Not only that, but also: "Aurinia also explored potentially acquiring or licensing other entities or assets during this time." So they did a lot of stuff in 7 months. Of course JP Morgan was doing most of that I guess.
All of which led to this: "The Board ultimately determined that none of the explored opportunities that were available to it to pursue were in the best near-term interests of the Company to execute on, and that the best path forward is for management to streamline its operations as it announced today and focus on the Company’s commercial execution."
We will now have to see what their focus on commercial execution brings as far as any changes to the plan and the results.
I still don't understand how they talked about to 60 companies in 6 months thats 10 a month! And they ended the talks after only 6 months It seems they were just trying to apease someone . Watch the tutes swoop in and grab all those sold shares and than do an upgrade to buy ! LOL
Well according to the ER, they were to commence “on or about Feb, 21”, so it could be. Still curious as to a small co GIA repurchasing shares.
Did they start the share buyback program today? We bounced off the 52 week low and ended up in the high fives.
Moving in the direction for u today
No, no dreaming needed. This is just a clear reality of the current situation.
As stated previously, this clearly looks like it is going into the fours if not, possibly lower. I think the threes will make a good reentry. The twos would be an absolute steal.
Sold covered calls on my entire position last week. I usually only do 20% but need to start collecting more from this.
I think Leerink published a note along the lines of Z's opinion .
There are however several biotech Co's interested in LN ...
Well, let me throw this out, as I know jack about this type of process. Were they marketing the company with a BO price in mind?
For example if you put your house on the market for 5 million bucks but it is only worth $500K will you get any offers?
So, anyone familiar with this strategic review can opine as to whether there was a top line number shopped around. If no number whatsoever
was shopped, and they still got no offers (which they didn't) then all are screwed.
If, however, there was an asking price that was grossly overpriced, then there still might be an opportunity at a more realistic valuation.
A bit of oversimplification of a complex situation. The single most important variable is the proven efficacy of Lupkynis, for a deadly disease, one for which there is no better treatment.
There were many headwinds for Aurinia (including Covid which made it just about impossible to promote the drug, not to mention the state of the economy and market).
It's a volatile situation, down one day, up the next! Aurinia is taking steps to move into a robust, self-sustaining state. They are not desperate to be bought immediately, which gives them a better bargaining position in the future.
Well what happened Zzat, is that they came out publicly and said nobody wants to buy them
My guess is another trip back to the $4’s then a slow climb back up
Don't want to spend much time going down this rabbit hole. AUPH CEO was on same board as Armistice founder, they were appointed at the same time.
2017
Cerecor appoints Steven Boyd and Peter Greenleaf to Board of Directors
https://www.manufacturingchemist.com/cerecor-appoints-steven-boyd-and-peter-greenleaf-to-board-of-directors--129269
Maybe same thing is happening here at AUPH as AYTU. Insider trading, shorting, and making sure CEO keeps his position come AGM voting. No idea though..
Armistice Capital Sued for ‘Looting,’ Insider Trades at Aytu Bio
https://news.bloomberglaw.com/litigation/armistice-capital-sued-for-looting-insider-trades-at-aytu-bio
2023
Court Document August 2023
https://cases.justia.com/federal/district-courts/colorado/codce/1:2020cv02849/200976/127/0.pdf
Chugging along is an appropriate descriptor…
Oh my God! What happened???
Did a patient die?? Did they discover an unknown toxicity?? Is the company running out of money?? NOPE! None of the above. We missed "estimates" by a few pennies. My feeling is the "estimators" had no clue and the company will continue to chug along and as it start showing a profit, either the PPS will go up, or there will be buyout. Not to worry.
Bigger question is where do we go from here as investors in Aurinia. I personally can’t stick with this company another 7 years. Still believe in the wonderful product Aurinia produces for its patients. There has to be some sort of solution.
I did say 6.00 and pete exceeded my expectations. when pete took over the stock was around 6.59 after 5 years as ceo we are down a 1.00.
and yes he is still pulling in his 1.3million
back to sleep mode
Well, at least they provided an honest, non sugar coated report on the offers.
Seven years of investment in AUPH for this. What a disappointment!
So do you think Armistice knew about this strategic review fail when the added over 3 millions shares a couple of days ago?
Very sorry to see this for you guys but this was expected IMO. Small bios just don’t work out usually for us retail investors. The buyout scenario is mostly a lottery dream.
Thanks. It seemed like it was taking way too long with no news.
what a kick in the teeth this is! no buyers wow
https://finance.yahoo.com/news/1-aurinia-stop-development-immunotherapies-111904453.html
Thanks for posting. Reason for late rise in sp today? Maybe more fireworks tomorrow.
2024-02-14 13G ARMISTICE CAPITAL, LLC 9,536,000 6.64 ownership
Interesting ... thanks for sharing. The KDIGO PR and Executive summary emphasize two big reasons for updating the KDIGO clinical practice guidelines quicker than most expected: (1) the novel add-on therapies and in particular VOC/LUP approved by FDA (hard to ignore the results shown in the patient registry for LN patients treated with VOC/Lup both as initial therapy in that it acts fast in reducing UPRC and increasing eGRF and works well as maintenance therapy -- ergo: VOC/Lup gets KDIGO's high certainty of evidence rating); and (2) LN is an aggressive, devastating disease that requires immediate treatment to prevent permanent damage and potential loss of kidneys. I have seen the devastating nature of kidney disease first hand in my family. Thank God for Auph's investment in solving LN after more than 20 years of failed attempts by others including BP to solve LN. WT
Who finds it strange that AUPH moves up earnings two weeks to right after Otsuka reports earnings? I wonder what reason AUPH had for doing it. Any theories out there?
Being covered by Healio
Chatter I am seeing is that, based on the new KDIGO guidelines, the relevant US docs treating LN class III and IV are expected to make VOC/Lupkynis part of a new SOC for such LN patients. It might be too early for data, but it would be great if they had some data to show impact of KDIGO 2024 guidelines. WT
Love the "take away chart" for the 2024 KDIGO guidelines. Seem's strong for Auph's VOC/Lupkynis for LN class III, IV, and V, particularly when you consider that VOC/Lupkynis is the only recommended option to receive KGIGO's high certainty of evidence rating. WT
https://stocktwits.com/watsonturtle/message/560875481
the comparison to Benlysta is in plain view right in their corporate presentation ... assumed you would have found that by now. Good luck. WT
WT. Are U referring to this trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392829/
Kiwi
WT. re
Jess. My wife's hands are not tied by her employer . She has no problem prescribing generic meds .
When it comes to Brand CKD drugs she often faces difficulty getting the drug for her patient because the insurers set up PA ( prior approval ) hurdles. ie document your patient has failed on all these drugs ...MMF , Benny etc ( as example ) first . Then if the brand drug is finally approved , the patient copay is often so high they can't afford it anyway . ...exception being when the drug manufacturer has programs in place to assist the patients ...usually in the first year or two of launch,
Kiwi
are you and kiwi one and the same person? don’t be ashamed to admit it, we won’t hold it against you.
Of course that is the case we should see a sharp rise in scripts right?
Kiwi, what say you on Watson’s take that insurance companies are now realizing that it can be more costly for them in the long run to use other options on LN which eventually will come down to dialysis or transplant in most cases? Using Lupy instead of the other options, believe it or not, can be a cheaper and quality of life extending option for patients and insurance companies. Maybe your wife knows that already but that her hands are tied by her direct or indirect employer…JMO.
90% of the PSFs are being converted in a short time because the Insurance companies are already recognizing that VOC safes the insurance companies and health industry a lot of money by avoiding dialysis and kidney transplant. Count our blessings that Auph followed through and solved a very difficult disease --- think about it ... for 20 plus years and the only option was MFF and steroids which accomplished very little for those suffering with LN. My family has a history of kidney diseases and nothing pisses me off more than to see the construct BS hurdles and needless delays to avoid coverage that was promised.
WT
nope ... referring to the specific data and the comparison to Benlysta ... hardly a difficult bar ... and the suggestion that the two drugs that can't swim on their own can somehow be combined to produce a good result ... had to laugh. I would be shocked if the trial that was terminated (paused if you prefer) would be restarted. They are not that dumb.
WT
Well thats easy ( flip the switch on ) ---lower the price ....at least lower than Benlysta ...or do you really think it's the MD's and not the insurers / payors who decide who gets the expensive Brand meds .
Kiwi
Z. Well I hope his wife is not a Nephrologist .
Nephrologists and their PA's treating dialysis patients deal with very difficult situations .
My wife , because of her experience , is considered " point of the spear ". Roughly 1 of her ( 120 ) dialysis patients dies every 2 weeks ...tough to deal with even tho she prescribes the best meds that the insurers agree to cover
Kiwi
WT. are U referring to this ?
“Today’s finding that hematuria – clinical evidence of active nephritis – resolves in the majority of patients receiving atacicept, supports an additional therapeutic benefit of targeting the source of this disease through atacicept’s dual inhibition of BAFF and APRIL,
By the way ...thx for the informed / well researched presentation of your views
Kiwi
Candidate & Indication | Development Stage | ||||
---|---|---|---|---|---|
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market | |
VOCLOSPORINLupus Nephritis (LN) | Preclinical Phase complete | Phase 1 Phase complete | Phase 2 Phase in progress | Phase 3 Phase not started | Market Phase not started |
Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.
Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).
Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.
Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.
Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:
In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.
The list of potential product benefits includes:
LN Critical Need | Voclosporin (based on AURA Results) | |
---|---|---|
Control of Active Disease | ||
Rapid Disease Control | ||
Lower Steroid Burden | ||
Impact on Extra-renal disease | ||
Convenient Treatment Regimen |
In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s
Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.
No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |